Imbria raises $57.5 million; appoints CEO
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing.
Backing the deal was a top-tier syndicate of life science investors led by new investor, Deep Track Capital. Additional new investors participating in the financing include AN Ventures, Catalio Capital Management and Cytokinetics, Inc. Existing investors RA Capital Management and SV Health Investors also contributed to the financing.
The privately-held Boston-based firm said the proceeds will be used to advance ninerafaxstat through a Phase IIb randomized, double-blind, placebo-controlled, clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM), called FORTITUDE-HCM. The company plans to initiate FORTITUDE-HCM in Q2 2025, with top-line data in late 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze